Overview:
Computer
system validation has been regulated by FDA for more than 30 years, as it
relates to systems used in the manufacturing, testing and distribution of a
product in the pharmaceutical, biotechnology, medical device or other
FDA-regulated industries. The FDA
requirements ensure thorough planning, implementation, integration, testing and
management of computer systems used to collect, analyze and/or report data.
Electronic
records and electronic signatures (ER/ES) came into play through guidelines
established by FDA in 1997, and disseminated through 21 CFR Part 11. This code describes the basic requirements
for validating and documenting ER/ES capability in systems used in an
FDA-regulated environment.
In
the early 2000s, FDA recognized they could not inspect every computer system at
every regulated company and placed the onus on industry to begin assessing all
regulated computer systems based on risk.
The level of potential risk, should the system fail to operate properly,
needed to be the basis for each company’s approach to developing a validation
approach and rationale as part of the planning process. System size, complexity, business
criticality, GAMP 5 category and risk rating are the five key components for
determining the scope and robustness of testing required to ensure data
integrity and product safety.
FDA’s
recent focus on data integrity during computer system validation inspections
and audits has brought this issue to the forefront of importance for compliance
of systems used in regulated industries.
These include all systems that “touch” product, meaning they are used to
create, collect, analyze, manage, transfer and report data regulated by
FDA. All structured data, including
databases, and unstructured data, including documents, spreadsheets,
presentations, images, audio and video files, amongst others, must be managed
and maintained with integrity throughout their entire life cycle.
So
what is next for the modernization of the processes involved in compliance for
FDA-regulated systems, keeping in mind the guidance documents provide thus
far? The FDA is embarking on a
modernization program to update their technology and processes for working with
industry to assure regulated products meet FDA compliance. There are numerous programs underway,
including partnerships with other agencies and industry to move forward as
technology continues to improve. The FDA
plans to take advantage of these technologies, just as industry is focused on
the same goal. The key is making sure
these are employed in a way that promotes public health, providing more
improved FDA-regulated products with fewer negative side effects and
issues. Plans will also enable FDA to
work with industry to move products to market faster, further improving public
health.
We
will explore the best practices and strategic approach for evaluating the
current processes involved in assuring computer systems used in the conduct
FDA-regulated activities are modernized and streamlined. Cloud computing, Software as a Service (SaaS),
automated computer system testing and mobile devices are just part of the mix
we can expect to explode in the near term.
Finally,
we will provide an overview of industry best practices, with a focus on data
integrity and risk assessment that can be leveraged to assist in all your GxP
work.
Areas
covered during the Session:
- Learn
how to identify “GxP” Systems
- Learn
about FDA’s current program for modernization of technology, and how this will
impact industry
- Learn
about FDA’s Technology Modernization Action Plan (TMAP), including what work is
underway and what is planned in the near term
- Discuss
the current state of Computer System Validation (CSV) approach based on FDA
requirements
- Learn
about the System Development Life Cycle (SDLC) approach to validation and how
this can be modernized through a more agile approach, including automated
testing for continuous validation
- We
will discuss cloud computing and Software as a Service (SaaS) systems that can
be embraced and validated effectively
- Discuss
the best practices for documenting computer system validation efforts,
including requirements, design, development, testing and operational
maintenance procedures, including ways to improve efficiency and effectiveness
- Understand
how to maintain a system in a validated state through the system’s entire life
cycle in a more cost-effective manner.
- Learn
how to assure the integrity of data that supports GxP work, despite changes and
advances in new technology
- Discuss
the importance of “GxP” documentation that complies with FDA requirements
- Learn
about the policies and procedures needed to support your validation process and
ongoing maintenance of your systems in a validated state
- Know
the regulatory influences that lead to FDA’s current thinking at any given time
- Finally,
understand the industry best practices that will enable you to optimize your
approach to validation and compliance, based on risk assessment, to ensure data
integrity is maintained throughout the entire data life cycle
- Q&A
Why
should you attend this training program?
This
webinar will help you understand in detail the application of FDA’s guidelines
for Computer System Validation (CSV), which is in accordance with the System
Development Life Cycle (SDLC) Methodology.
This is critical in order to develop the appropriate validation strategy
and achieve the thoroughness required to prove that a system does what it
purports to do. It also ensures that a
system is maintained in a validated state throughout its entire life cycle,
from conception through retirement.
The
SDLC will provide a framework for validation planning, allowing the attendee to
understand all of the phases and deliverables required during validation. The end result will be a very well documented
validation effort that will stand up to FDA scrutiny during an audit, and
assure that the data housed and/or processed using the validated computer
system will be maintained with great integrity.
It
is important to remember that in addition to validating a computer system
subject to FDA compliance, the system must be maintained in a validated state
throughout its lifecycle, until the system is retired or otherwise no longer
used. This webinar will describe the
policies, procedures, training and other underlying support elements that are needed
to ensure ongoing maintenance of a system in a validated state.
In
addition, FDA has heavily focused its resources on inspection targeting Data
Integrity (DI). During the past ten
years, the percentage of Form 483 citations and Warning Letters with issues
related to DI has increased dramatically, and continues to do so through
2019. We will provide the requirements
related to DI, examples of FDA findings, and will cover the industry best
practices that will help you mitigate this potential risk.
What industries will benefit from your training:
Manufacturing, Testing, Packaging and Distribution companies in the following industries that are regulated by FDA are required to follow GxPs:
- Pharmaceutical
(for drug products introduced using a medical device)
- Medical
Device
- Biologicals
(for biological products introduced using a medical device)
- Tobacco
(based on the Tobacco Control Act of 2009)
- E-Liquid/Vapor
(based on the “Deeming” Act of 2016)
- E-Cigarette
(based on the “Deeming” Act of 2016)
- Cigar
(based on the “Deeming” Act of 2016)
- Third-Party
companies that support those in the above industries, including Contract
Research Organizations (CROs)
- Colleges
and Universities offering programs of study in Clinical Trial Management and
Regulatory Affairs/Matters related to FDA
Who
Should Attend?
- Information
Technology Analysts
- QC/QA
Managers
- QC/QA
Analysts
- Clinical
Data Managers
- Clinical
Data Scientists
- Analytical
Chemists
- Compliance
Managers
- Laboratory
Managers
- Automation
Analysts
- Manufacturing
Managers
- Manufacturing
Supervisors
- Supply
Chain Specialists
- Computer
System Validation Specialists
- GMP
Training Specialists
- Business
Stakeholders responsible for computer system validation planning, execution,
reporting, compliance, maintenance and audit
- Consultants
working in the life sciences industry who are involved in computer system
implementation, validation and compliance
- Auditors
engaged in the internal inspection of labeling records and practices
Carolyn Troiano has more than 35 years of experience in computer system validation in the pharmaceutical, medical device, animal health, tobacco and other FDA-regulated industries. She is currently an independent consultant, advising companies on computer system validation and large-scale IT system implementation projects.
During her career, Carolyn worked directly, or on a consulting basis, for many of the larger pharmaceutical companies in the US and Europe. She developed validation programs and strategies back in the mid-1980s, when the first FDA guidebook was published on the subject, and collaborated with FDA and other industry representatives on 21 CFR Part 11, the FDA’s electronic record/electronic signature regulation.
Carolyn has participated in industry conferences. She is currently active in the PMI, AITP, and RichTech, and volunteers for the PMI’s Educational Fund as a project management instructor for non-profit organizations.
Enrollment Options
Tags: Technology Modernization Action Plan, FDA, Carolyn Troiano, Webinar, Amorit Education